Mental Health Services Research

, Volume 5, Issue 3, pp 149–153

Administrative Prescription Review Procedures and Use of Atypical Antipsychotic Medications in the Department of Veterans Affairs

  • Robert Rosenheck
  • Douglas Leslie
Article

Abstract

Atypical antipsychotic medications vary in cost with limited evidence of differences in effectiveness. Administrative prescription review has been proposed as a way of encouraging use of less expensive medication when there is no specific clinical justification for using more expensive medication. This study examined data from a national GAO survey of 876 veterans affairs (VA) psychiatrists, and national administrative data on the proportion of veterans actually receiving atypical antipsychotic medications. The proportion of psychiatrists in each region reporting that they did not feel free to prescribe expensive drugs when indicated was negatively correlated with the proportion of patients who filled prescriptions for clozapine, the most expensive atypical. The proportion reporting review procedures for prescribing olanzapine was significantly and negatively correlated with the proportion of veterans actually receiving prescriptions for olanzapine and, positively associated with the proportion prescribed risperidone. Nondirective administrative review procedures in VA are significantly associated with actual prescribing patterns and may generate modest cost savings in the prescription of atypical antipsychotic medication.

schizophrenia antipsychotic medication cost containment psychopharmacology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Essock, S. M., Frisman, L. K., Covell, N., & Hargreaves, W. A. (2000). Cost-effectiveness of clozpaine comapred with conventional antipsychoticmedication for patients in state hospitals. Archives of General Psychiatry, 57(10), 987-994.Google Scholar
  2. Leslie, D., & Rosenheck, R. A. (2001). The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia. Journal of Nervous and Mental Disease 189(6): 377-383.Google Scholar
  3. Leslie, D., & Rosenheck, R. A. (2002). Third annual report on pharmacotherapy of schizophrenia in the Department of Veterans Affairs (2002). West Haven, CT: Northeast Program Evaluation Center.Google Scholar
  4. Rosenheck, R. A., Cramer, J., Xu, W., Grabowski, J., Douyon, R., Thomas, J., Henderson, W. et al. (1998). Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Health Services Research 33(5):1235-1259.Google Scholar
  5. Rosenheck, R. A., Cramer, J., Xu, W., Thomas, J., Henderson, W., & Frisman, L. K. et al. (1997). A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337: 809-815 (For the Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia.)Google Scholar
  6. Rosenheck, R. A., Leslie, D. L., & Sernyak, M. E. (2001). From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Medical Care, 39(3):302-308.Google Scholar
  7. U.S. General Accounting Office. (2002 April). VA health care: Implementation of prescribing guideline for atypical antipsychotic drugs generally sound. (GAO 02-579). Washington, DC.Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • Robert Rosenheck
    • 1
  • Douglas Leslie
    • 2
    • 3
  1. 1.Yale Departments of Psychiatry and Epidemiology and Public HealthNew Haven
  2. 2.New England Mental Illness Research, Education, and Clinical CenterWest Haven
  3. 3.Yale Departments of Psychiatry and Epidemiology and Public HealthNew Haven

Personalised recommendations